4-methyl-3-(3-pyridyl)aniline | 264617-04-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-methyl-3-(3-pyridyl)aniline
• 英文别名: 4-methyl-3-pyridin-3-yl-phenylamine；4-Methyl-3-(3-pyridinyl)-benzenamine；4-methyl-3-pyridin-3-ylaniline
• CAS: 264617-04-1
• 化学式: C₁₂H₁₂N₂
• 分子量: 184.241
• InChiKey: UVDGDGFCTXUHSV-UHFFFAOYSA-N

物化性质

• 沸点：
  353.2±30.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methyl-3-(3-pyridyl)aniline 在 platinum on carbon 盐酸 、 氢气 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0~110.0 ℃ 、1.03 MPa 条件下， 反应 66.0h， 生成
  参考文献：
  名称：

  [EN] BRUTON'S TYROSINE KINASE INHIBITORS
  [FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON

  摘要：

  本发明提供了用作Btk抑制剂的化合物、其组合物以及使用方法。

  公开号：

  WO2011029046A1
• 作为产物：
  描述：

  2-溴-4-硝基甲苯 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 、 tin(ll) chloride 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 12.0h， 生成 4-methyl-3-(3-pyridyl)aniline
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c

文献信息

• Imidazo-pyrimidine derivatives as ligands for gaba receptors
  申请人：——

  公开号：US20020193385A1

  公开（公告）日：2002-12-19

  A class of 3-phenylimidazo[1,2-&agr;]pyrimidine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and further substituted on the phenyl ring by alkyl, trifluoromethyl, alkoxy or one or two halogen atoms, especially fluoro, are selective ligands for GABA A receptors, in particular having good affinity for the &agr;2 and/or &agr;3 and/or &agr;5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

  一类3-苯基咪唑[1,2-&agr;]嘧啶衍生物，苯环的间位被取代，取代基可以是直接连接或通过氧原子或-NH-键桥接的取代芳基或杂环芳基，苯环上进一步被取代为烷基，三氟甲基，烷氧基或一个或两个卤素原子，特别是氟，是GABAA受体的选择性配体，特别是对其中的&agr;2和/或&agr;3和/或&agr;5亚基具有良好的亲和力，因此对于治疗和/或预防中枢神经系统的不良症状，包括焦虑，惊厥和认知障碍具有益处。
• Indole derivatives as 5-HT receptor antagonist
  申请人：SmithKline Beecham p.l.c.

  公开号：US20030105139A1

  公开（公告）日：2003-06-05

  The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

  本发明涉及具有药理活性的杂环化合物，其制备过程，含有它们的组合物以及它们在治疗中枢神经系统疾病如焦虑症方面的应用。
• BRUTON'S TYROSINE KINASE INHIBITORS
  申请人：Bui Minna

  公开号：US20120157443A1

  公开（公告）日：2012-06-21

  The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

  本发明提供了一种作为Btk抑制剂有用的化合物，以及其组成物和使用相应的方法。
• Bruton's tyrosine kinase inhibitors
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：US10577374B2

  公开（公告）日：2020-03-03

  The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

  本发明提供了可用作 Btk 抑制剂的化合物、其组合物及其使用方法。
• IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP1381606B1

  公开（公告）日：2005-07-20